Acerus Biopharma

Acerus Pharmaceuticals was a Canadian specialty pharmaceutical company focused on commercializing and developing branded prescription products in men’s health, urology, and selected women’s health indications. Its marketed portfolio included Natesto, a testosterone nasal gel for male hypogonadism, Noctiva for nocturia due to nocturnal polyuria acquired through Serenity Pharmaceuticals, Estrace in Canada, and Gynoflor in Canada. The company also advanced Tefina, a low-dose intranasal testosterone product for female sexual dysfunction, but it remained an investigational asset. Acerus operated through direct commercialization in the United States and Canada and through licensed distributors in other territories. The company entered Canadian CCAA proceedings in January 2023, indicating financial distress and effective cessation of normal operating status as an independent going concern.